Cytek Biosciences Inc (CTKB) Stock Price, Quote & News

Company Profile

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; g...

Industry: Medical Devices

Sector: Healthcare

Phone: 877 922 9835

Website: cytekbio.com

Address:

47215 Lakeview Boulevard, Fremont, United States

Manusia1 Nov. 17 at 8:11 AM

$CTKB 312 watchers. why so low?

0 · Reply

jdlman Nov. 17 at 3:58 AM

$CTKB lets have another great week here

0 · Reply

Joby099 Nov. 17 at 1:02 AM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

SadyK189 Nov. 16 at 11:48 PM

Top Stocks to watch next week 2 / 2: $QNRX $GLTO $TXMD $APUS $CTKB QNRX: Initially alerted for 14.40 - 15.10. It went till 15.46 afterwards. Getting better on 4hours chart. Key support at 11.80 - 12.40. Next key level to test is 15.90 - 16.45. Currently at 14.33 TXMD: Looking good on daily chart. Key support at 1.35 - 1.50. Next key level to test is 2.25 - 2.45. Currently at 1.88 GLTO: Looking good on daily chart. key support at 19 - 21. Next key level to test is 32.50 - 33.95. Currently at 27.62 CTKB: Good close of daily candle. Key support at 4.6 - 4.95. Next key level to test is 6.75 - 7.10. Currently at 5.90 APUS: Looking good on 4hours chart. Key support at 2.40 - 2.65. Next key level to test is 3.7 - 3.95. Currently at 3.21

0 · Reply

Joby099 Nov. 16 at 6:59 PM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

Joby099 Nov. 16 at 2:30 PM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

Joby099 Nov. 15 at 9:29 PM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

avoid Nov. 15 at 8:24 PM

$CTKB https://www.sec.gov/Archives/edgar/data/1061983/000189761225000526/xslSCHEDULE_13G_X01/primary_doc.xml

2 · Reply

GSP Nov. 15 at 8:02 PM

$SPY $PALI $ONDS $CYCU $CTKB

0 · Reply

FonsieTrader Nov. 15 at 4:42 PM

$CTKB — Massive Weekly Shift in Momentum It just delivered a strong weekly close, breaking out of a long multi-month downtrend with conviction. Technical Highlights: • Trendline breakout on high volume — confirms buyers stepping in aggressively. • Price reclaimed the full Keltner channel — a clear signal of trend reversal. • MFI & OBV both rising → accumulation is real and consistent. • ADX turning up — momentum strengthening after a long base. • Weekly structure now points toward a bigger move developing. In As long as it holds above 5.00, this breakout has legs. Next major resistance sits near 9.20 Powerful weekly close → momentum shift → upside unlocked.

0 · Reply

TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026

Nov 6, 2025, 5:00 PM EST - 10 days ago

Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

Nov 6, 2025, 4:05 PM EST - 10 days ago

Cytek Biosciences to Participate in Upcoming Investor Conferences

Nov 5, 2025, 8:51 PM EST - 11 days ago

Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 11 days ago

Cytek Biosciences Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 5:00 PM EDT - 18 days ago

Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

Oct 22, 2025, 4:05 PM EDT - 25 days ago

Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 5:00 PM EDT - 4 weeks ago

Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth

Sep 17, 2025, 9:00 AM EDT - 2 months ago

Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q's Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control

Sep 10, 2025, 5:00 PM EDT - 2 months ago

Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA

Sep 10, 2025, 12:57 PM EDT - 2 months ago

Cytek Biosciences, Inc. (CTKB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 7, 2025, 4:25 AM EDT - 3 months ago

Cytek Biosciences, Inc. (CTKB) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 3 months ago

Cytek Biosciences Reports Second Quarter 2025 Financial Results

May 29, 2025, 5:00 PM EDT - 6 months ago

Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

May 28, 2025, 4:05 PM EDT - 6 months ago

Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

May 11, 2025, 8:30 PM EDT - 6 months ago

Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Cytek Biosciences Reports First Quarter 2025 Financial Results

May 5, 2025, 8:14 AM EDT - 6 months ago

Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?

Apr 29, 2025, 5:00 PM EDT - 7 months ago

Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

Apr 28, 2025, 8:15 AM EDT - 7 months ago

Why Cytek Biosciences Should Beat Q1 Earnings Expectations

Apr 24, 2025, 4:05 PM EDT - 7 months ago

Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 18, 2025, 5:00 PM EDT - 8 months ago

Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

Feb 28, 2025, 9:49 AM EST - 9 months ago

Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript

Feb 27, 2025, 4:05 PM EST - 9 months ago

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

Feb 13, 2025, 4:05 PM EST - 9 months ago

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Jan 9, 2025, 9:30 AM EST - 11 months ago

Upgrading Cytek Biosciences Stock On An Upcoming Catalyst

Jan 2, 2025, 8:00 AM EST - 11 months ago

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 8:00 AM EST - 11 months ago

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

Nov 20, 2024, 4:05 PM EST - 1 year ago

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 5:00 PM EST - 1 year ago

Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

Nov 7, 2024, 5:00 PM EST - 1 year ago

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

Nov 5, 2024, 8:26 PM EST - 1 year ago

Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript

Sep 18, 2024, 5:00 PM EDT - 1 year ago

Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe

Sep 12, 2024, 3:20 PM EDT - 1 year ago

Cytek Announces Resignation of Chief Operating Officer Chris Williams

Aug 21, 2024, 5:00 PM EDT - 1 year ago

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

Aug 11, 2024, 4:25 AM EDT - 1 year ago

Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 5:00 PM EDT - 1 year ago

Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm

May 30, 2024, 4:05 PM EDT - 1 year ago

Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 5:30 PM EDT - 1 year ago

1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China

May 23, 2024, 9:17 AM EDT - 1 year ago

Lab Instrument Industry Update - New Commercial Entrants

AKYA BNGO DHR LAB MASS OMIC QGEN

May 20, 2024, 5:30 PM EDT - 1 year ago

Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

May 12, 2024, 3:24 AM EDT - 1 year ago

Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:05 PM EDT - 1 year ago

Cytek Biosciences Reports First Quarter 2024 Financial Results

Apr 30, 2024, 5:30 PM EDT - 1 year ago

Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe

Apr 29, 2024, 9:00 AM EDT - 1 year ago

Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024

Mar 20, 2024, 4:33 AM EDT - 1 year ago

Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Cytek® Biosciences Names William McCombe Chief Financial Officer

Mar 7, 2024, 5:30 PM EST - 1 year ago

Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions

Feb 28, 2024, 7:24 PM EST - 1 year ago

Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 5:05 PM EST - 1 year ago

Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Manusia1 Nov. 17 at 8:11 AM

$CTKB 312 watchers. why so low?

0 · Reply

jdlman Nov. 17 at 3:58 AM

$CTKB lets have another great week here

0 · Reply

Joby099 Nov. 17 at 1:02 AM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

SadyK189 Nov. 16 at 11:48 PM

0 · Reply

Joby099 Nov. 16 at 6:59 PM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

Joby099 Nov. 16 at 2:30 PM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

Joby099 Nov. 15 at 9:29 PM

$UVXY $CTKB $ZEC.X $SPY $LTC.X

0 · Reply

avoid Nov. 15 at 8:24 PM

$CTKB https://www.sec.gov/Archives/edgar/data/1061983/000189761225000526/xslSCHEDULE_13G_X01/primary_doc.xml

2 · Reply

GSP Nov. 15 at 8:02 PM

$SPY $PALI $ONDS $CYCU $CTKB

0 · Reply

FonsieTrader Nov. 15 at 4:42 PM

0 · Reply

Joby099 Nov. 15 at 3:40 PM

$UVXY $CTKB $ZEC.X $SPY $LTC.X Great pick ! https://www.youtube.com/watch?v=nehVp_RQQx8&t=557s

0 · Reply

Ophirnews Nov. 15 at 3:07 PM

Most investors have no clue what Cytek Biosciences ($CTKB) actually does — and that’s exactly why it still trades like a hidden gem. CTKB isn’t a biotech. It’s a life-science tools company powering the infrastructure behind cell analysis. Think “the NVIDIA of immune profiling

1 · Reply

LibertarianTreehugger Nov. 14 at 7:50 PM

What's up with $CTKB today?

1 · Reply

nspyre Nov. 14 at 6:59 PM

$CTKB people sleepin on this

0 · Reply

DARKP00L Nov. 11 at 5:15 PM

$CTKB 12:00 on Nov. 11 2025 Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5 #tradeideas

0 · Reply

JarvisFlow Nov. 11 at 5:00 PM

Piper Sandler has updated their rating for Cytek Biosciences ( $CTKB ) to Overweight with a price target of 7.5.

0 · Reply

khmerxbxboi Nov. 8 at 4:37 PM

$CTKB = thank you for the headache and gain ;)

0 · Reply

BioTechHealthX Nov. 8 at 3:48 PM

$CTKB Cytek Biosciences is seeing double-digit growth in instrument placements and rising recurring revenue — CTKB may be undervalued. https://biotechhealthx.com/biotech-news/why-cytek-biosciences-ctkb-could-be-a-hidden-medtech-gem/

0 · Reply

d_risk Nov. 6 at 4:28 PM

$CTKB - Cytek Biosciences Inc. Common Stock - 10Q - Updated Risk Factors CTKB’s latest 10-Q risk factors spotlight sharper challenges in product strategy, forecasting, and global expansion, with expanded warnings on supply chain, tariffs, export controls, reliance on government/academic sales, distributor risks, cybersecurity, data privacy, IP protection, ownership concentration, and evolving tax/regulatory threats. #Biotechnology #Cybersecurity #SupplyChainRisk #GlobalExpansion #ProductStrategy 🟢 Added 🟠 Removed https://d-risk.ai/CTKB/10-Q/2025-11-05

0 · Reply

ShortyBear_5582 Nov. 6 at 2:55 PM

$CCLD $STGW $CTKB hmmm

0 · Reply

_www_larval_com_ Nov. 6 at 2:42 PM

$FTEL -13%[26%] $ACVA -10%[-38%] $GDTC -10%[2%] $DYN -8%[-13%] $CTKB 6%[18%] most notable movement within the first minutes of trading.

0 · Reply

Ilivalis Oct. 30 at 2:59 PM

$CTKB inside info? Who knows….

0 · Reply

Market Cap	703.26M
Revenue (ttm)	200.45M
Net Income (ttm)	-6.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3.00%
Debt to Equity Ratio	0.00

Volume	6,944,500
Avg Vol	1,005,948
Day's Range	N/A - N/A
Shares Out	127.87M
Stochastic %K	86%
Beta	1.33
Analysts	Sell
Price Target	$5.00